| Company Name: | Arena Pharmaceuticals Inc | | | Ticker Symbol: | ARNA | | CIK Number: | 0001080709 | | WWW Address: | http://www.arenapharm.com |
| CEO: | Mr. Amit D. Munshi | | No. of Employees: | 106 |
| Common Issue Type: | CS | | Business Description: | Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors to address major therapeutic areas like cardiovascular & metabolic diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 55.32 |  0.0 | 52.88 | 55.55 | | 57.25 | 55.00 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2,742.2 | 49.6 | 0.00 | -0.63 | 0.00 | 0.0 | 0.0 | 59.13 - 31.97 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 55.88 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 2,742.2 | mil |
| Latest Shares Outstanding | 49.6 | mil |
| Earnings pS (EPS) | -0.63 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 92,629 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 49.5 | mil |
| Float as % of Shares Outstanding | 1.0 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 2.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 6.40 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | -720.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 3.5 | % |
| Return on Assets (ROA) | -5.7 | % |
| Return on Equity (ROE) | -7.2 | % |
| Return on Capital Invested (ROCI) | -6.8 | % |
| Current Ratio | 15.4 | |
| Leverage Ratio (Assets/Equity) | 1.1 | |
| Interest Cover | -23.4 | |
| Total Debt/Equity (Gearing Ratio) | 0.09 | |
| LT Debt/Total Capital | 8.0 | % |
| Working Capital pS | 8.69 | $ |
| Cash pS | 0.00 | $ |
| Book-Value pS | 25.08 | $ |
| Tangible Book-Value pS | 12.23 | $ |
| Cash Flow pS | 12.74 | $ |
| Free Cash Flow pS | 12.71 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.13 | |
| Price/Tangible Book Ratio | 0.00 | |
| Price/Cash Flow | 4.2 | |
| Price/Free Cash Flow | 4.2 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 5.4 | | 517,764 | 2,938,803 |
| 4 Weeks | 59.13 | 47.92 | 51.81 | 7.9 | | 661,819 | 12,574,567 |
| 13 Weeks | 59.13 | 42.54 | 45.48 | 22.9 | | 490,897 | 30,926,568 |
| 26 Weeks | 59.13 | 34.50 | 40.55 | 37.8 | | 487,429 | 60,441,310 |
| 52 Weeks | 59.13 | 31.97 | 48.34 | 15.6 | | 532,987 | 133,246,949 |
| YTD | 59.13 | 38.18 | - | 38.9 | | 478,876 | 51,718,669 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 55.55 | 54.53 | 49.81 | 45.59 | 43.93 | 0.00 | 0.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -0.26 | 0.0 | -0.22 |
| Income | | 0.0 | |
| Dividend | | 0.0 | |
| Capital Spending | | NA | |
| R&D | -22.62 | NA | -18.37 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 8.4 | 8.4 | 116.9 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.09 | 0.09 | 0.35 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 62.72 |
| Current Ratio | 15.4 |
| Quick Ratio (Acid Test) | 15.1 |
| Liquidity Ratio (Cash) | 20.28 |
| Receivables Turnover | 4.8 |
| Average Collection Period | 75 |
| Working Capital/Equity | 71.1 |
| Working Capital pS | 8.71 |
| Cash-Flow pS | -2.81 |
| Free Cash-Flow pS | -2.83 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 0.05 |
| Financial Leverage Ratio (Assets/Equity) | 0.1 |
| Debt Ratio | 7.7 |
| Total Debt/Equity (Gearing Ratio) | 0.09 |
| LT Debt/Equity | 0.08 |
| LT Debt/Capital Invested | 0.0 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | -23.4 |
| Interest/Capital Invested | 0.94 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.00 |
| Tobin's Q Ratio | 3.85 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -15.77 |
| Enterprise Value (EV)/Free Cash Flow | -15.49 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 0.00 |
| Price/Book Ratio - LTM | 2.13 |
| Price/Cash Flow Ratio | 4.2 |
| Price/Free Cash Flow Ratio - LTM | 4.2 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 5.4 |
| 5-Y Low P/E Ratio | 0.9 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 38 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.68 |
| Tangible Book Value pS - LTM | 12.23 |
| Book Value pS - LTM | 25.08 |
| Capital Invested pS | 12.23 |
| Cash pS - LTM | 0.00 |
| Cash Flow pS - LTM | 12.74 |
| Free Cash Flow pS - LTM | 12.71 |
| Earnings pS (EPS) | -0.63 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -739.59 |
| Free Cash Flow Margin 5YEAR AVG | -337.27 |
| Net Profit Margin | -1.6 |
| Net Profit Margin - 5YEAR AVRG. | -2.1 |
| Equity Productivity | 0.03 |
| Return on Equity (ROE) | -0.1 |
| Return on Equity (ROE) - 5YEAR AVRG. | -0.9 |
| Capital Invested Productivity | 0.03 |
| Return on Capital Invested (ROCI) | -0.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -0.4 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -0.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | -0.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | |
| EBITDA Margin - LTM | -720.0 |
| EBIT Margin - LTM | -740.9 |
| Pre-Tax Profit Margin | -3.4 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -3.4 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | |
| Revenue per Employee | 92,629 |
| Net Income per Employee | |
| Average Collection Period | |
| Receivables Turnover | 4.8 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 34.46 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.04 |
| Fixed Assets Turnover | 0.08 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.11 |
| Revenue per $ Plant | 0.78 |
| Revenue per $ Common Equity | 0.03 |
| Revenue per $ Capital Invested | 0.03 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 265.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 640.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 640.1 |
|
|  
| | |  |  | | |
